Journal of Lung Cancer Epidemiology

Journal of Lung Cancer Epidemiology

Current Issue Volume No: 1 Issue No: 1

Review-article Article Open Access
  • Available online freely Peer Reviewed

  • Challenger Treatment Of Various Cancers With T Cells Engineering

    Heidari Alireza 1 2 3 4     Locci Elena 1 2 3     Raymond Silvia 1 2 3     Gobato Ricardo 5
       

    1 Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA. 

    2 BioSpectroscopy Core Research Laboratory, California South University, 14731 Comet St. Irvine, CA 92604, USA. 

    3 Cancer Research Institute (CRI), California South University, 14731 Comet St. Irvine, CA 92604, USA. 

    4 American International Standards Institute, Irvine, CA 3800, USA. 

    5 Green Land Landscaping and Gardening, Seedling Growth Laboratory, 86130-000, Parana, Brazil 

    Abstract

    Through T-cell engineering, researchers at the California South University (CSU) Cancer Research Institute (CRI) have shown that tumor growth can be stopped in a variety of cancers and prevented from spreading to other tissues. Findings from this study are the result of decades of research by Professor Ph.D. A. Heidari and our team of CSU, who discovered a protein called AH that can inhibit the growth and spread of cancer cells in several different ways. They become in the tissues of the body. The T cells were armed with MDA-7/AH to target cancer more widely. The engineering of T cells to produce MDA-7/AH causes cancer cells to be destroyed regardless of the expression of the target molecules. The tumor site is often very hostile to immune cells. It was found in the research that MDA-7/AH can help T cells proliferate and increase the number of cancer cells. The T cells were armed with MDA-7/ AH to target cancer more widely. The engineering of T cells to produce MDA-7/AH causes cancer cells to be destroyed regardless of the expression of the target molecules. The tumor site is often very hostile to immune cells. We discovered that MDA-7/AH can help T cells proliferate and increase the number of cancer cells.
    Author Contributions
    Received Nov 22, 2021     Accepted Apr 05, 2022     Published Apr 13, 2023

    Copyright© 2023 Heidari Alireza, et al.
    License
    Creative Commons License   This work is licensed under a Creative Commons Attribution 4.0 International License. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    Competing interests

    The authors have declared that no competing interests exist.

    Funding Interests:

    Citation:

    Heidari Alireza, Locci Elena, Raymond Silvia, Gobato Ricardo et al. (2023) Challenger Treatment Of Various Cancers With T Cells Engineering Journal of Lung Cancer Epidemiology. - 1(1):43-75
    DOI

    Introduction

    Introduction

    At the subcellular level, MDA-7/AH binds to cell surface receptors and instructs them to make and release more copies of the MDA-7/AH protein. If the cell is normal, the protein is easily secreted and does not cause harm, but if the cell is cancerous, MDA-7/AH causes damage and eventual cell death not only in the primary tumor but also in the surrounding metastases; This is the cause of death in 90% of patients. As a result of this process, the immune system produces memory T cells that can be destroyed if the tumor returns to normal. Tumor levels of AH also prevent the formation of blood vessels, tumors that are very hungry and need nutrients to continue growing uncontrollably. In mice with prostate cancer, melanoma, or other cancer metastases, MDA-7 / AH-expressing T cells slowed or stopped cancer progression better than unmodified T cells. The researchers also found that arming T cells with MDA-7/AH allowed them to survive better and proliferate in the microenvironment of the tumor (the space around the cancerous mass). 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100.

    Results

    Results and Discussion

    The site of the tumor is often very hostile to immune cells. We discovered that MDA-7/AH can help T cells proliferate and increase the number of cancer cells. In the clinic, the procedure involves extracting the patient's own T cells from tumor samples, genetically engineering them to express MDA-7/AH, growing millions of copies of the cells in the laboratory, and finally transplanting them back into the patient. Using federal production standards, this method is generally safer and less invasive. CAR-T cells can also be engineered to express MDA-7/AH. For greater effectiveness, MDA-7/AH cells may be used in conjunction with other therapies. Clinical trials using various AH transmission methods are currently underway for several cancers. A phase 1 trial using adeno (cold-like virus) to deliver MDA-7/IL24 to a tumor has shown about 44% efficacy against various forms of cancer.

    According to Liu Z. et al. (2021) taken together, arming T cells with tumoricidal and immune-potentiating MDA-7/IL24 confers new capabilities of eradicating antigen-negative cancer cell clones and improving T-cell expansion within tumors. This promising approach may be used to optimize cellular immunotherapy for treating heterogeneous solid cancers and provide a mechanism for inhibiting tumor escape.

    The results of Liu Z. et al. (2021) appear to be promising, as well as the techniques employed by the research team led by Professor Ph.D. A. Heidari and our team of CSU, discovered two new ways to induce tumor cell death, activating ferroptosis, where: first, iron-dependent cell death due to oxidative stress, and second, oxidative stress. Therefore, cell death can also be induced in a different way. Both types of cell death must be caused by drugs at the same time to eliminate the majority of the tumor mass.

    Conclusion

    Conclusions

    The T cells were armed with MDA-7/AH to target cancer more widely. The engineering of T cells to produce MDA-7/AH causes cancer cells to be destroyed regardless of the expression of the target molecules. The tumor site is often very hostile to immune cells. We discovered that MDA-7/AH can help T cells proliferate and increase the number of cancer cells.

    A techniques employed by the research team led by biologist Dr. Raymond discovered two new ways to induce tumor cell death, activating ferroptosis, where: first, iron-dependent cell death due to oxidative stress, and second, oxidative stress. Therefore, cell death can also be induced in a different way. Both types of cell death must be caused by drugs at the same time to eliminate the majority of the tumor mass.

    Affiliations:
    Affiliations: